Ocugen (OCGN)
(Delayed Data from NSDQ)
$0.99 USD
-0.04 (-3.53%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.99 0.00 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCGN 0.99 -0.04(-3.53%)
Will OCGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OCGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCGN
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
OCGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends
5 Biotech Breakthrough Stocks to Watch in 2025
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
Other News for OCGN
Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Ocugen (OCGN) Advances Gene Therapy Initiatives Amidst Strategic Changes
Q2 2025 Ocugen Inc Earnings Call Transcript
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Ocugen outlines three licensing applications and 2026 commercialization plans while advancing gene therapy trials